PMID- 21168540
OWN - NLM
STAT- MEDLINE
DCOM- 20110425
LR  - 20131121
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 11
IP  - 2
DP  - 2011 Feb
TI  - Effects of astilbic acid on airway hyperresponsiveness and inflammation in a 
      mouse model of allergic asthma.
PG  - 266-73
LID - 10.1016/j.intimp.2010.12.002 [doi]
AB  - Bronchial asthma is characterized by chronic lung inflammation, airway 
      hyperresponsiveness (AHR), and airway remodeling. Astilbic acid, extracted from 
      the medicinal herb Astilbe chinensis, is used as a headache remedy in traditional 
      medicine and has anti-pyretic and analgesic effects. However, the effect of 
      astilbic acid on asthma remains to be established. In the present study, we 
      therefore examined the effect of astilbic acid in a mouse model in which asthma 
      was established by sensitization and challenge with ovalbumin (OVA). Astilbic 
      acid inhibited OVA-induced AHR to inhaled methacholine and significantly 
      suppressed the levels of T-helper 2-type cytokines (including IL [interleukin]-4, 
      IL-5, and IL-13) and inflammatory cells (including eosinophils) in 
      bronchoalveolar lavage (BAL) fluid. Histochemical analysis revealed reduced 
      goblet cell hyperplasia and mucus production, as well as attenuated 
      eosinophil-rich leukocyte infiltration, in the astilbic acid-treated group, 
      compared with OVA-challenged mice. Moreover, the compound significantly inhibited 
      synthesis of IL-4-, IL-5-, IL-13-, IL-17-, and eotaxin-encoding mRNA following 
      asthma induction in lung tissue, in addition to suppressing the immunoglobulin E 
      (IgE) response to asthma in both BAL fluid and serum. Our results indicate that 
      astilbic acid has great potential as a therapeutic candidate for the treatment of 
      asthma.
CI  - Copyright A(c) 2010 Elsevier B.V. All rights reserved.
FAU - Yuk, Ji-Eun
AU  - Yuk JE
AD  - Immune Modulator Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Yang-chung ri, O-chang uep, 363-883, Republic of Korea.
FAU - Lee, Mee-Young
AU  - Lee MY
FAU - Kwon, Ok-Kyoung
AU  - Kwon OK
FAU - Cai, Xing-Fu
AU  - Cai XF
FAU - Jang, Ha-Young
AU  - Jang HY
FAU - Oh, Sei-Ryang
AU  - Oh SR
FAU - Lee, Hyeong-Kyu
AU  - Lee HK
FAU - Ahn, Kyung-Seop
AU  - Ahn KS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101217
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (3beta,6beta-dihydroxyolean-12-en-27-oic acid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 6SMK8R7TGJ (Oleanolic Acid)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/isolation & 
      purification/*therapeutic use
MH  - Asthma/*drug therapy/immunology
MH  - Bronchoalveolar Lavage Fluid/cytology/immunology
MH  - Cytokines/immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Immunoglobulin E/blood
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Molecular Structure
MH  - Oleanolic Acid/administration & dosage/*analogs & derivatives/isolation & 
      purification/therapeutic use
MH  - Respiratory System/drug effects/*immunology
MH  - Saxifragaceae/chemistry
MH  - T-Lymphocytes, Helper-Inducer/drug effects/immunology
EDAT- 2010/12/21 06:00
MHDA- 2011/04/26 06:00
CRDT- 2010/12/21 06:00
PHST- 2010/07/06 00:00 [received]
PHST- 2010/11/08 00:00 [revised]
PHST- 2010/12/02 00:00 [accepted]
PHST- 2010/12/21 06:00 [entrez]
PHST- 2010/12/21 06:00 [pubmed]
PHST- 2011/04/26 06:00 [medline]
AID - S1567-5769(10)00405-4 [pii]
AID - 10.1016/j.intimp.2010.12.002 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2011 Feb;11(2):266-73. doi: 10.1016/j.intimp.2010.12.002. 
      Epub 2010 Dec 17.